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The only lymphocytes required for protection against fecal rotavirus shedding after intranasal immunization of BALB/c (H-2d) mice with a
chimeric rotavirus VP6 protein (MBP∷VP6) and the mucosal adjuvant LT(R192G) are CD4+ T cells. The purpose of this study was to identify
CD4+ T cell epitopes within VP6 that might be responsible for this protection. To make this determination, spleen cells obtained from BALB/c
mice following intranasal immunization with MBP∷VP6/LT(R192G) were stimulated in vitro with either MBP∷VP6 or overlapping VP6
peptides containing ≤30 amino acids (AA). The numbers of memory (CD44high) CD4+ T cells stimulated to produce TH1 and TH17 cytokines
(IFNγ and IL-17), as well as the quantities of these cytokines released into the cell supernatants, were then measured relative to those produced in
mock-stimulated cells from the same animals. One epitope expected to be found was the VP6 14-mer AA289–302, previously identified as a CD4
+
T cell epitope in H-2d mice. This was not observed but instead the only VP6 epitope identified was AA242–259, the dominant CD4
+ T cell epitope
previously reported after oral, live rotavirus immunization.
© 2007 Elsevier Inc. All rights reserved.Keywords: Rotavirus; VP6 vaccine; CD4 T cells; EpitopesIntroduction
Development of safe and effective vaccines against rotavirus
has been a public health priority for many years and two
vaccines, Rotarix and RotaTeq, are now being licensed world-
wide (Ruiz-Palacios et al., 2006; Vesikari et al., 2006). Both are
live rotaviruses that are delivered orally and each has been found
to be safe after administration in placebo-controlled trials of
>60,000 infants. Even so, the absolute safety of these vaccines
will only be determinable during post-licensure surveillance.
The experience with the Rotashield vaccine, marketed in the
USA in 1998–99 but withdrawn due to a rare side effect
(intussusception) (Murphy et al., 2001), provides ample proof of
the reality of unexpected post-licensure complications. Efficacy
trials conducted in both developed and less-developed nations⁎ Corresponding author. Fax: +1 513 636 0950.
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doi:10.1016/j.virol.2007.01.041have shown that both Rotarix and RotaTeq are highly protective
against severe rotavirus disease. However, the efficacies of each
against rotaviruses belonging to emerging serotypes are yet to be
determined and neither has been evaluated in Third World
nations where earlier live rotavirus vaccine candidates have
failed (De Mol et al., 1986; Georges-Courbot et al., 1991;
Hanlon et al., 1987; Lanata et al., 1989). Thus, there is a need to
develop and evaluate second generation rotavirus vaccines that
are based on a different paradigm, that is, they are non-living.
Several non-living rotavirus vaccine candidates have been
developed and evaluated in animal models including, among
others, inactivated rotavirus particles, virus-like particles, and
the intermediate capsid rotavirus protein VP6 (Choi et al., 1999;
McNeal et al., 1998, 1999a,1999b; O'Neal et al., 1997). When
recombinant human or murine rotavirus VP6 proteins were
expressed in Escherichia coli as fusion proteins containing
maltose binding protein (MBP) and administered intranasally or
orally to mice along with an effective adjuvant [attenuated,
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tently suppressed intestinal rotavirus antigen production by
>95% after murine rotavirus challenge (Choi et al., 1999,
2002). Protection remained fully intact for at least 1 year and the
only lymphocytes required for this excellent memory response
were CD4+ T cells based on studies in H-2d BALB/c mice
(McNeal et al., 2002; VanCott et al., 2006).
It has been reported that the porcine rotavirus YM VP6
protein contains a 14-amino-acid (AA) CD4+ T cell (H-2d)
epitope in its VP6 protein spanning AA289–302 of this 397 AA
protein (Banos et al., 1997). When the same peptide obtained
from the murine EDIM rotavirus, which differed by one AA
from the YM 14-mer, was delivered intranasally to BALB/c
mice along with an effective adjuvant, it elicited haplotype-
specific protection comparable to that of the complete VP6
protein (Choi et al., 2000). This suggested that the AA289–302
14-mer may be the dominant CD4+ Tcell epitope specific for H-
2d mice within the VP6 protein.
To make this determination, we evaluated the abilities of
overlapping peptides within VP6 to activate memory CD4+ T
cells obtained from the spleens of BALB/c mice immunized
intranasally with MBP∷VP6/LT(R192G). We previously
found that when the gene for the recombinant VP6 protein
of the EDIM strain of murine rotavirus was divided into two
equal halves and expressed in E. coli, the carboxyl terminal
half of the protein (AA197–397) provided significantly
(P<0.001) greater protection against EDIM replication than
the amino terminal half (AA1–196) (99.8 vs. 79.4% reductions
in fecal shedding of EDIM antigen, respectively) (Choi et al.,
2000). Based on this observation and the finding that CD4+ T
cells were the only memory cells required for protection after
VP6 immunization of BALB/c mice, it was assumed that the
carboxyl terminal half of the VP6 protein was more likely to
contain CD4+ T cell epitopes than the amino terminal half of
this protein. Therefore, only overlapping peptides present in
the carboxyl half of the VP6 protein were examined for their
abilities to activate memory CD4+ T cells. Because the
previously identified CD4+ T cell epitope (AA289–302) is
present in this region of VP6 and elicited excellent protection
when used as an immunogen in BALB/c mice (Choi et al.,
2000), it was anticipated that the peptide containing this 14-
mer would be readily shown to activate memory CD4+ T cells
obtained from spleens of MBP∷VP6/LT(R192G)-immunized
mice. As will be reported, this was not the result obtained
and, in fact, another peptide was the only one found within
the carboxyl terminal half of the VP6 protein to stimulate an
identifiable, in vitro CD4+ T cell response.
Results
The VP6 (H-2d restricted) CD4+ T cell epitope (AA 289–302) is
not immunodominant after intranasal immunization of H-2d
BALB/c mice with MBP∷VP6/LT(R192G)
To determine if the 14 AA VP6 peptide (AA289–302) was
an immunodominant CD4+ T cell epitope during MBP∷VP6
immunization of BALB/c mice, spleen cells obtained 4 weeksafter the second of two intranasal immunizations with EDIM
VP6 (i.e., MBP∷VP6) together with LT(R192G) were
stimulated in vitro with either this EDIM 14-mer or
MBP∷VP6. CD4+ CD44high (memory) T cell responses were
then measured by intracellular cytokine (IFNγ or IL-17)
production using fluorescence-activated cell sorting (FACS).
These two cytokines were chosen because they had been found
to be the cytokines most associated with memory CD4+ T cell
activation in VP6-immunized mice (McNeal et al., 2006;
Smiley et al., in press; VanCott et al., 2006). Production of
both cytokines was greatly increased in memory CD4+ T cells
after MBP∷VP6 stimulation but no increase in production of
either cytokine was found after stimulation with the AA289–302
14-mer relative to that found in mock-stimulated spleen
cells obtained from immunized mice (Figs. 1A and B).
Similarly, when the cytokines released into the culture fluids
of these spleen cells were measured by ELISA, stimulation
with MBP∷VP6 induced large increases in both IFNγ and
IL-17 relative to mock-stimulated cells while 14-mer
stimulation had no effect on the levels of either cytokine
(Figs. 1C and D).
To insure that the 14-mer was capable of stimulating CD4+
T cell responses in vitro, mice were intranasally immunized
with this peptide [2 doses of 50 μg with 10 μg of LT
(R192G)] and their spleen cells were stimulated with either
MBP∷VP6 or the 14-mer. It was found that the protein and
peptide stimulated comparably large amounts of both IFNγ
and IL-17 in the splenic CD4+ CD44high cells obtained from
these mice (results not shown). Thus, the 14-mer was clearly
capable of stimulating memory CD4+ T cells with the proper
receptors. Based on these results, it appeared that the 14-mer
was not an immunodominant CD4+ T cell epitope during
intranasal immunization of BALB/c mice with MBP∷VP6/LT
(R192G).
VP6 peptide AA232–261 contains a CD4
+ T cell epitope
identifiable after immunization of H-2d BALB/c mice with
MBP∷VP6/LT(R192G)
Because CD4+ T cells were found to be the only
lymphocytes required for protection after MBP∷VP6/LT
(R192G) immunization (McNeal et al., 2002), and signifi-
cantly greater protection was elicited by the carboxyl terminal
half of VP6 than its amino terminal half, it seemed likely that
the distal half of this molecule was the most likely to contain
identifiable CD4+ T cell epitopes (Choi et al., 2000). To
identify these epitopes, spleen cells from MBP∷VP6/LT
(R192G)-immunized BALB/c mice were stimulated in vitro
with each of 11 overlapping peptides that comprised the distal
half of the VP6 protein (AA197–397), and cytokine (IFNγ or IL-
17) accumulation levels in the culture fluids were measured in
comparison to MBP∷VP6-stimulated and mock-stimulated
cells (Table 1). As noted in a previous publication (Choi et
al., 2000), the lengths of these peptides ranged from 18 to 30
amino acids and overlapped by 0 to 13 residues between
adjacent peptides. As expected, MBP∷VP6 stimulation
resulted in large increases in the levels of both cytokines
Fig. 1. Production of cytokines (IL-17 and IFNγ) by spleen cells obtained from mice immunized intranasally with MBP∷VP6 and LT(R192G) and either mock
stimulated or stimulated with the VP6 peptide AA289–302. Spleens from MBP∷VP6-immunized adult BALB/c mice were pooled (4 mice each) and either mock
stimulated or were stimulated with 9 μg of MBP∷VP6 or 50 μg of VP6 AA289–302 for 24 h, the last 5 h of which was in the presence of brefeldin A. Supernatants were
harvested for quantification of secreted IL-17 and IFNγ (C and D). Cells were also tagged with conjugated antibodies to CD44 and CD4 and stained with antibody to
either IL-17 or IFNγ prior to FACS analysis, and the percentages of CD4+ cells staining for CD44high and either IL-17 or IFNγ were determined (A and B).
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stimulated appreciable levels of these cytokines (Table 1).
Therefore, this appeared to be the only peptide in this region
of the VP6 molecule that contained a CD4+ T cell epitope
identifiable by this method after MBP∷VP6/LT(R192G)
immunization.
Mapping of a CD4+ T cell epitope within the C-terminal half of
VP6 utilized during MBP∷VP6/LT(R192G) immunization of
BALB/c mice
To determine which region of peptide #3 (AA232–261) was
responsible for stimulating cytokine production in CD4+ T cells
of MBP∷VP6/LT(R192G)-immunized BALB/c mice, a series
of 7 overlapping peptides were synthesized that encompassed
this peptide. Each contained 15 amino acids that differed by 3
amino acids from the adjacent peptides (except peptide E that
differed from peptide D by 6 amino acids; Fig. 2). Only peptides
E–G were able to stimulate either IL-17 or IFNγ production inCD4+ CD44high T cells obtained from the spleens of
MBP∷VP6/LT(R192G)-immunized BALB/c mice (Figs. 3A
and B) or IL-17/IFNγ release into the culture medium of these
stimulated spleen cells (Figs. 3C and D). Even though peptides
E–G each stimulated lower quantities of CD4+ T cells
producing IL-17 or IFNγ than the original peptide #3 as well
as lower amounts of these cytokines, the differences were small.
However, differences in cytokine production levels stimulated
by peptide #3 were between 6- and 60-fold lower than those
stimulated by MBP∷VP6 (see Fig. 1). Thus, the complete VP6
protein stimulated much better T cell responses than any of the
VP6 peptides tested individually.
Since the effects of antigen presentation to CD4+ T cells can
be augmented if the presented peptide extends several amino
acids on one or both sides beyond the MHC II core binding site
(Bitmansour et al., 2002; Kaufmann et al., 2004), it was next
determined if either an 18 or 20 AA peptide within the newly
identified CD4+ T cell epitope region could provide better
CD4+ T cell stimulation than the 15 AA peptides E–G or the 30
Table 1
Quantities of IL-17 and IFNγ released into the supernatants after in vitro
stimulation of spleen cells isolated from MBP∷VP6/LT(R192G) immunized
mice a
In vitro stimulation IL-17 (pg/ml) IFNγ (pg/ml)
Mock 122 18,546
MBP∷VP6 48,324 161,960
Peptide 1 AA197–221 316 8702
Peptide 2 AA227–244 26 3144
Peptide 3 AA232–261 5142 60,847
Peptide 4 AA249–277 147 6175
Peptide 5 AA266–295 52 1265
Peptide 6 AA283–307 126 4155
Peptide 7 AA300–329 41 5869
Peptide 8 AA317–346 105 6002
Peptide 9 AA334–355 26 2186
Peptide 10 AA351–380 108 7835
Peptide 11 AA368–397 45 3254
a Groups of 3 to 6 animals were intranasally immunized with 2 doses of 9 μg
of MBP:VP6 and 10 μg of LT(R192G). Spleen cells were isolated 4 weeks after
the last immunization, pooled, and stimulated with 50 μg of the above peptides.
IL-17 and IFNγ levels were measured in the supernatants after 24 h of
incubation by ELISA.
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(R192G)-immunized BALB/c mice were stimulated with either
a VP6 18-mer (AA242–259) or 20-mer (AA240–259) that
overlapped much of the region contained in peptides E–G
(Fig. 2), and cytokine release from these stimulated spleen cells
was measured. Both peptides stimulated nearly identical levels
of IL-17 or IFNγ and these levels were not significantly
different from those stimulated by the original peptide #3
(AA232–261) (Figs. 4A and B). They were, however, signifi-
cantly (P < 0.001) lower than those stimulated by MBP∷VP6.
Therefore, it appeared that both of these peptides contained the
complete and only CD4+ T cell epitope for BALB/c mice
identifiable by these methods in the C-terminal half of the
EDIM VP6 protein. It should also be noted that when BALB/c
mice were intranasally immunized with 2 doses of either the
AA242–259 or AA240–259 peptide or peptide #3 along with LT
(R192G), spleen cells obtained 4 weeks after the second
immunization could also be readily stimulated in vitro by their
specific immunizing peptide to produce CD4+ CD44high cells
expressing IL-17 or IFNγ (results not shown).Fig. 2. Synthetic peptides of EDIM VP6 to be usVP6 peptides AA242–259 and AA240–259 elicit protection of
BALB/c mice against EDIM shedding that is equivalent to the
protection stimulated by immunization with either peptide #3
(AA232–261) or EDIM MBP∷VP6
To insure that the EDIM VP6 peptides AA242–259 and
AA240–259 found to contain an identifiable CD4
+ (H-2d) T cell
epitope could also elicit protection of mice against EDIM
shedding as was observed after MBP∷VP6 immunization,
BALB/c mice were intranasally administered 2 doses of either
peptide or, as controls, MBP∷VP6, or peptide #3 (AA232–261),
along with LT(R192G) as adjuvant. When the mice were
challenged with EDIM 4 weeks after the second immunization,
the average levels of protection in the 4 groups ranged from
87% to 97% with the higher levels found in the MBP∷VP6- and
peptide #3-immunized mice (Table 2). However, none of the
differences in the levels of protection were significant. There-
fore, the H-2d CD4+ T cell epitope identified in VP6 after
intranasal immunization provided excellent protection of
BALB/c mice. Although not included as negative controls in
this experiment, we have previously reported that many VP6
peptides provided no protection when used to immunize BALB/
c mice under these same conditions (Choi et al., 2000).
Discussion
Because intranasal immunization with the chimeric rotavirus
MBP∷VP6 protein together with LT(R192G) as adjuvant elicits
nearly complete protection against murine rotavirus shedding in
adult mice (Choi et al., 1999, 2002) and the only lymphocytes
required for protection in the immunized animals have been
shown to be CD4+ T cells (McNeal et al., 2002), it was of
interest to identify the CD4+ epitopes in VP6 responsible for
this protection. It was assumed that if VP6-specific memory
CD4+ T cells, as defined by the presence of high levels of
membrane-bound CD44, were generated and retained in mice
immunized with MBP∷VP6/LT(R192G), these cells would be
found in the spleens of the immunized animals and would be
identifiable by their abilities to up-regulate the production of
cytokines after in vitro stimulation with either MBP∷VP6 or
VP6 peptides containing CD4+ T cell epitopes. Two cytokines
whose production was expected to be up-regulated were theed for immunization or in vitro stimulation.
Fig. 3. Production of cytokines (IL-17 and IFNγ) by spleen cells obtained from mice immunized intranasally with MBP∷VP6 and LT(R192G) and either mock
stimulated or stimulated with either VP6 peptide #3 (AA232–261) or 15-mer overlapping peptides from within AA227–262 of VP6 (peptides A–G; see Fig. 2). Spleens
from MBP∷VP6-immunized adult BALB/c mice were pooled (4–6 mice each) and either mock stimulated or stimulated with 50 μg of each VP6 peptide for 24 h, the
last 5 h of which was in the presence of brefeldin A. Supernatants were harvested for quantification of secreted IL-17 and IFNγ (C and D). Cells were also tagged with
conjugated antibodies to CD44 and CD4 and stained with antibody to either IL-17 or IFNγ prior to FACS analysis, and the percentages of CD4+ cells staining for
CD44high and either IL-17 or IFNγ were determined (A and B).
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previous evidence obtained using splenic or intestinal lympho-
cytes from MBP∷VP6-immunized mice (McNeal et al., 2006;
Smiley et al., in press; VanCott et al., 2006). It was also assumed
that the previously identified CD4+ T cell epitope within VP6
specific for H-2d mice (AA289–302) (Banos et al., 1997) would
be readily identified by this method in MBP∷VP6-immunized
BALB/c (H-2d) mice. Although this 14 AA peptide has itself
been found, after intranasal immunization together with LT
(R192G), to provide excellent protection against rotavirus
shedding after murine rotavirus challenge (Choi et al., 2000),
and CD4+ CD44high spleen cells obtained from mice immu-
nized with this 14-mer on the day of challenge could be readily
stimulated to produce both IFNγ and IL-17, this peptide was
unable to elicit in vitro up-regulation of these cytokines in CD4+
CD44high spleen cells obtained from MBP∷VP6/LT(R192G)-
immunized mice.
Since the C-terminal half of VP6 had been shown to elicit
significantly greater protection than the N-terminal region of this
protein (Choi et al., 2000), 11 overlapping peptides comprising
the C-terminal half of VP6, ranging from 18 to 30 AA in length,
were used to stimulate spleen cells from MBP∷VP6/LT(R192G)-immunized mice to determine which peptide, if any,
contained a CD4+ T cell epitope that was recognized by the
immunized mice. Only one peptide (AA232–261) was able to
stimulate IFNγ and IL-17 production and this was not the
peptide (AA283–307) that contained the original 14-mer
(AA289–302). Further analyses with additional peptides revealed
that the CD4+ T cell epitope contained in the AA232–261 peptide
was within the 18-mer AA242–259. This epitope was essentially
identical to the major CD4+ T cell epitope identified by Jaimes
et al. (2005) after in vitro stimulation of liver infiltrating
lymphocytes obtained from either C57BL/6 (H-2b) or BALB/c
(H-2d) mice orally immunized with a live rotavirus. In contrast
to the negative results we obtained after stimulation with the
AA289–302 14-mer using CD4
+ T cells from spleens of
MBP∷VP6/LT(R192G)-immunized BALB/c mice, these
authors reported that a 15-mer (AA289–303) was able to stimulate
responses in liver CD4+ T cells of orally infected BALB/c mice,
but these responses were significantly lower than those
stimulated by AA245–259 (Jaimes et al., 2005). Our inability to
stimulate spleen cells of MBP∷VP6-immunized mice using the
AA289–302 peptide could have been due to several reasons such
as (1) our limit of detection was too high, (2) memory CD4+ T
Fig. 4. Production of cytokines (IL-17 and IFNγ) by spleen cells obtained from
mice immunized intranasally with MBP∷VP6 and LT(R192G) and either mock
stimulated or stimulated with either VP6 peptide #3 (AA232–261) or 18-mer
(AA242–259) or 20-mer (AA240–259) peptides from within this region of VP6 (see
Fig. 2). Spleens were obtained fromMBP∷VP6-immunized adult BALB/c mice
(3 mice/group) and harvested cells from each mouse were either mock
stimulated or were stimulated with 9 μg of MBP∷VP6 or 50 μg of each VP6
peptide for 24 h. Supernatants were then harvested for quantification of secreted
IL-17 or IFNγ. *Indicates groups in which cytokine levels were significantly
(P<0.05) greater than in the mock-stimulated group; #indicates VP6 peptide-
stimulated groups in which cytokine levels were significantly (P<0.001) less
than found in the MBP∷VP6 stimulated group.
Table 2
Protection against EDIM shedding after intranasal immunization of BALB/c
mice with VP6 peptides AA242–259, AA240–259, or AA232–261, or with
MBP∷VP6
Antigen used for
immunization a
Quantities of fecal rotavirus
antigen shed (ng/mouse/day) b
% Protection c
None 3168±4460
AA242–259 309±789
d 90
AA240–259 412±841
d 87
AA232–261 109±254
d 97
MBP∷VP6 161±579 d 95
a Groups of 8 mice were immunized intranasally 2 times, 14 days apart, with
50 μg of peptide or 9 μgMBP:VP6 together with 10 μg LT(R192G). Four weeks
after the second immunization, mice were challenged with 105 SD50 of wt
EDIM. Stools were collected daily for 7 days prior to determination of the
quantities of fecal rotavirus antigen shed.
b Mean quantity of rotavirus antigen shed ±SD over 7 days post-challenge.
c Percent protection is the percent decrease in mean quantity of rotavirus
antigen shed during the 7 days after challenge due to immunization as compared
to the unimmunized group.
d Significantly (P<0.001) less than unimmunized mice but not significantly
different from other immunized groups.
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spleens of immunized mice, or (3) responses to this epitope
were more efficient after oral immunization with live rotavirus
than after intranasal immunization with MBP∷VP6 and
adjuvant. Regardless of the reason, it appears that the same
VP6 CD4+ T cell epitope (AA242–259) is dominant after
immunization by both methods and is also dominant for more
than one haplotype of mouse.
It is of interest to note that the effectors of protection appear
to differ after oral, live rotavirus infection and intranasal VP6
immunization. For the former, antibody has been identified as
the primary effector (Franco and Greenberg, 1995; McNeal et
al., 1995; VanCott et al., 2006), while, as already noted, CD4+ T
cells appear to be the only lymphocytes required for protection
after intranasal immunization with MBP∷VP6/LT(R192G)
(McNeal et al., 2002, 2006). Although neutralizing antibodies
against the VP7 and VP4 proteins have been identified as majoreffectors of protection after live rotavirus immunization,
antibodies against VP6 have also been found to be protective
in mice (Burns et al., 1995; Feng et al., 2002). The mechanism
of anti-VP6 antibody protection has been suggested to be
intracellular neutralization within intestinal enterocytes during
transport of polymeric antibody through these cells into the
intestinal lumen (Burns et al., 1995; Feng et al., 2002). Since
expansion of virus-specific B cells and production of rotavirus
antibody have been found to be largely dependent on CD4+ T
cells after live rotavirus infection (McNeal et al., 1997; VanCott
et al., 2001), these T cells presumably play crucial roles in
production of protective anti-VP6 antibodies. Therefore, CD4+
T cell epitopes within VP6 are expected to be important in
protection after either oral, live rotavirus immunization,
particularly with heterotypic rotaviruses (VanCott et al.,
2006), or intranasal VP6 immunization (McNeal et al., 2002,
2006).
Although we identified a peptide (AA242–259) within VP6
that was able to stimulate memory CD4+ T cells produced after
MBP∷VP6/LT(R192G) immunization of mice, the responses
stimulated by this peptide were much lower than those
stimulated by MBP∷VP6 itself. There are several possible
explanations for this observation such as poorer uptake of the
AA242–259 peptide relative to the complete VP6 protein by
antigen presenting cells or less efficient presentation of the
synthetic peptide relative to its counterpart generated in APCs
after processing of VP6. Another explanation is that since
immunization and in vitro stimulation in these studies were with
MBP∷VP6, it was possible that the CD4+ T cell responses
measured after in vitro stimulation were against T cell epitopes
within MBP rather than VP6, thus making MBP∷VP6
potentially more effective for in vitro stimulation than any
VP6 peptide. This possibility was eliminated by demonstrating
that essentially identical numbers of IFNγ- and IL-17-produ-
cing CD44high CD4+ T cells were found in spleen cells obtained
from MBP∷VP6-immunized mice after in vitro stimulation
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(results not shown).
The more likely explanation is that the CD4+ Tcell responses
stimulated by VP6 are the combined effects of multiple weak
CD4+ T cell epitopes within this protein. We already reported
that 6 of the 11 synthetic peptides composing the C-terminal
half of VP6 used in this study were able to stimulate significant
protection against rotavirus shedding in BALB/c mice immu-
nized intranasally with LT(R192G) (Choi et al., 2000).
Furthermore, in the previous study, the protection stimulated
by peptide #3 containing AA242–259 was no greater than that
elicited by the other 5 peptides (#2, 4, 6, 8, and 11). Since CD4+
T cells are the only lymphocytes needed for protection after
MBP∷VP6/LT(R192G) immunization (McNeal et al., 2002), it
is likely that each of these protective peptides contained at least
one, albeit weak, CD4+ T cell epitope. If this is true, it follows
that the identified CD4+ T cell epitope within peptide #6
(AA289–302) is also subdominant after VP6 immunization.
There have been limited studies concerning hierarchy of epitope
recognition by CD4+ T cells and how this influences the course
of acute viral infection (Brookes et al., 1995; Harcourt et al.,
2004; Shoukry et al., 2004). However, such hierarchies clearly
exist and in one particularly informative study with hepatitis C
virus infection of chimpanzees it was demonstrated that the
appearance of CD4+ T cells against subdominant epitopes only
appeared after virus replication was controlled (Shoukry et al.,
2004). During a second infection 7 years later, responses to all
epitopes were accelerated but the hierarchy of dominance
remained. Whether responses to potentially subdominant CD4+
T cell epitopes within VP6 would be measurable with increased
time after immunization, or if such responses would be
detectable after a booster immunization months after the first
immunization remains to be determined.
Materials and methods
Virus
The murine strain of rotavirus (EDIM) used in this study was
originally obtained from M. Collins (Microbiological Associ-
ates, Bethesda, MD). The wild-type (wt) EDIM virus used to
challenge mice after vaccination was a pool made from stool
specimens of infected neonatal mice which were processed as
previously described (McNeal et al., 2002) and contained
5×106 focus forming units per milliliter.
Mouse strain
Six-week-old female BALB/c (H-2d) mice were purchased
from Harlan (Indianapolis, Indiana). Mice were housed in
microisolation cages and shown to be rotavirus negative
before use in these studies by analyzing serum samples for
the presence of rotavirus antibodies as previously described
(McNeal et al., 1999a,1999b). All animal procedures were
conducted in accordance with the Cincinnati Children's
Hospital Research Foundation Institutional Animal Care and
Use Committee.VP6 protein and VP6 peptides used for immunization and
in vitro stimulation
The construction of the plasmid containing the EDIM VP6
gene, the expression of the VP6 protein in E. coli as a chimera
with maltose binding protein (MBP∷VP6), and the purification
of the expressed MBP∷VP6 protein have been described
previously (Choi et al., 1999). Synthetic peptides were derived
from the amino acid sequence of the carboxyl terminal half of
the VP6 protein (AA 197 to 397). Peptides designated 1 through
11 ranged from 18 to 30 AA and the overlapping sequences
ranged from 0 to 13 AA in length as described in a previous
publication (Choi et al., 2000). A 14-AA peptide (AA289–302)
within peptide #6, previously determined to be a protective
epitope, was also synthesized (Choi et al., 2000). In addition,
overlapping 15-AA peptides were synthesized from AA227–262
and designated A throughG (Fig. 2). Finally, peptides AA242–259
and AA240–259, 18 and 20 AA in length, respectively, were
synthesized as well (Fig. 2). Peptides were synthesized by
Quality Control Biochemicals, Inc. (Hopkinton, MA) or by
Sigma-Genosys (The Woodlands, TX) as previously described
(Choi et al., 2000). The purity of the peptides was >95% based
on mass spectral and reverse-phase high-pressure liquid chro-
matography analyses.
Immunization of mice
Mice received two intranasal immunizations of MBP∷VP6
(9 μg) and adjuvant (10 μg) under light sedation induced by
isoflourane (Abbot Laboratories, Chicago, IL) as used in
previous studies (Choi et al., 1999, 2000, 2002). The adjuvant
used was the genetically attenuated E. coli heat labile toxin LT
(R192G). Immunizations were separated by 2 weeks. Four
weeks after the second immunization, animals were either
challenged with 105 shedding dose-50 (SD50) of wt EDIM by
oral gavage to measure protection against fecal rotavirus
shedding or they were sacrificed and their spleen cells were
isolated and used for in vitro stimulation studies. Additionally,
groups of mice were also immunized (i.n.) with two doses of
50 μg/dose of peptides AA242–259, AA240–259 or AA232–261
along with LT(R192G) as adjuvant to determine the abilities of
these peptides to protect against EDIM shedding after
challenge. This concentration of peptide was selected because
it was the same as that previously employed and had been found
to permit maximal protection (Choi et al., 2000).
Measurement of CD4+ T cell responses
MBP∷VP6-immunized BALB/c mice were sacrificed and
their spleens were removed. The spleen cells from two to six
animals in each group were pooled for analysis for most of the
experiments in order to have a sufficient quantity for the large
number of assays to be performed with each set of cells. Spleen
cells were isolated from individual MBP∷VP6-immunized
animals (3 animals per group) in experiments where peptides
AA242–259, AA240–259 or AA6232–261 were used for in vitro
stimulation. Single cell suspensions of spleen cells were made
417M.M. McNeal et al. / Virology 363 (2007) 410–418and red blood cells were lysed with 8.3 mg/ml of ammonium
chloride in 0.01 M Tris, pH 7.4. Lymphocytes were washed
and resuspended in complete RPMI medium (Gibco, Inc.,
Grand Island, NY) containing 10% fetal bovine serum, 2 mM
L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin,
100 μg/ml streptomycin, 2.5 μg/ml Amphotericin B, 100 μM
MEM non-essential amino acids, and 55 μM 2-mercaptoetha-
nol. Spleen cells (1×107) were cultured in 24-well tissue culture
plates (Falcon, BD Biosciences, Bedford, MA) in 1 ml of
complete RPMI for 24 h during which time the cells were either
mock stimulated or stimulated with 9 μg of MBP∷VP6 or 50 μg
of one of the peptides described above. The 24-h period was
selected because shorter periods produced less measurable
responses and longer periods resulted in increased levels of
background stimulation. During the last 5 h of culture, the cells
were incubated in the presence of brefeldin A (BD PharMingen,
San Diego, CA) to inhibit cytokine secretion. Supernatants from
the cultures were harvested and frozen for quantification of
secreted cytokines using ELISA kits for IFNγ (Pierce
Biotechnology, Inc., Rockford, IL) and IL-17 (R&D Systems,
Minneapolis, MN) as instructed by the manufacturers. The
levels of secreted cytokines measured were expressed as pg/ml.
The limit of detection for IFNγ and IL-17 was 50 and 10 pg/ml,
respectively.
To stain for intracellular cytokine production, R-Phycoer-
ythrin (PE)-conjugated antibodies for IFNγ (clone XMG1.2)
and IL-17 (clone TC11-18H10.1), fluorescein isothiocyanate
(FITC)-conjugated antibody to CD4 (clone RM4-4), allophy-
cocyanin (APC)-conjugated antibody to CD44 (clone IM7) and
isotype controls, all purchased from BD PharMingen, were used
at concentrations recommended by the manufacturer. After in
vitro stimulation, the cells were incubated with purified
monoclonal antibody to block Fc receptors (clone 2.4G2) and
then stained with antibodies to CD4 and CD44. After being
fixed and permeabilized according to the manufacturers'
instructions using a GolgiPlug kit (BD PharMingen), cells
were stained with PE-conjugated antibody against either IL-17
or IFNγ. Data were acquired using a FACSCaliber and analyzed
by CELLQuest software (BD Bioscience, San Jose, CA). Cells
were gated on the lymphocyte population by forward and side
scatter determination and 200,000 cells were acquired. Cells
were then gated on the CD4+ population and the percentages of
CD4+ cells staining for CD44high and either IL-17 or IFNγwere
determined.
Detection of rotavirus antigen in mouse stools and
determination of protection
To measure the quantities of rotavirus shed in fecal
specimens of BALB/c mice after challenge, stool samples
were collected daily for 7 days after EDIM challenge. Two
fecal pellets were collected from each mouse and placed into
1.0 ml of Earle's balanced salt solution and stored at −20 °C
until analyzed. Samples were thawed, homogenized and
centrifuged (1500×g, 5 min) to remove debris before being
analyzed for rotavirus antigen. Quantities of rotavirus antigen
shed were determined in nanograms per milliliter of stoolspecimen by an ELISA using methods previously described
(McNeal et al., 1999a,1999b). Protection was measured as the
percent reduction in shedding when comparing the mean
antigen shed per mouse per day in the immunized groups to
the mean antigen shed per mouse per day in the unimmunized
groups during the 7 days following EDIM challenge.
Statistical methods
All the analyses were performed using the statistical software
package SAS Version 9.1.3. The level of significance was 0.05.
For comparing the amount of shedding across the groups, the
mean rotavirus shedding amounts over 7 days after EDIM
challenge was used. The statistical method for all analyses was a
one-factor analysis of variance. When the number of groups
being compared was >2, a Bonferroni adjusted multiple
comparison procedure was used.
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